In summary, our results demonstrated that erastin could reverse ABCB1-mediated docetaxel resistance in ovarian cancer, suggesting that the combination of erastin and docetaxel may expand the limited options for chemo-resistant ovarian cancers. Here, ABCB1 is linked to ovarian carcinoma.